| (AstraZeneca) D702BC00001 / ARTEMIDE-Lung02 | A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 | Dr Rosalyn Juergens | Open to recruitment | NCT06692738 |
| (AstraZeneca) D702FC00001 / ARTEMIDE-Lung03 | A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03) | Dr Rosalyn Juergens | Open to recruitment | NCT06627647 |
| (CCTG) BR.36 | A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung Cancer | Dr Rosalyn Juergens | Suspended/On hold | NCT04093167 |
| (Gilead Sciences) GS-US-600-6165 / EVOKE-SCLC-04 | A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Dr Peter Ellis | Open to recruitment | NCT06801834 |
| (Merck) MK-1084-004 | A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50% | Dr Peter Ellis | Open to recruitment | NCT06345729 |
| (Merck) V940-009 / INTerpath-009 | A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy | Dr Rosalyn Juergens | Open to recruitment | NCT06623422 |
| (TheRas) TBBO8520-101 / ONKORAS-101 | A Phase 1a/1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination with Pembrolizumab in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study | Dr Peter Ellis | Open to recruitment | NCT06343402 |
| (AstraZeneca) TROPION-Lung17 / D763QC00001 | A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations. | Dr Rosalyn Juergens | Open to recruitment | NCT07291037 |
Find a Trial
Contact Us